Pfizer defends Norvasc patent from Synthon

10 September 2006

World drug giant Pfizer says that a federal court in the Middle District of North Carolina has upheld its US patent covering amlodipine besylate, the active ingredient in Norvasc, the world's most-prescribed branded medicine for hypertension. The patent had been challenged by the generic manufacturer, USA-based Synthon Pharmaceuticals.

Judge James Beaty ruled that the patent is valid and thereby infringed by the generic manufacturer's product. The decision, which is subject to appeal, prohibits Synthon from launching a generic version of the drug until September 2007.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight